细胞因子释放综合征
医学
嵌合抗原受体
细胞激素风暴
不利影响
神经毒性
免疫学
细胞疗法
免疫系统
细胞因子
T细胞
肿瘤科
内科学
毒性
细胞
生物
传染病(医学专业)
疾病
遗传学
2019年冠状病毒病(COVID-19)
作者
Uri Greenbaum,Jeremy Ramdial,Amanda Olson,Yago Nieto,Paolo Strati,Sairah Ahmed,Sattva S. Neelapu,Sudhakar Tummala,Linda Chi,Elizabeth J. Shpall,Partow Kebriaei
摘要
As the field of cancer therapeutics moves increasingly toward targeted and cellular therapies, this evolution comes with new hurdles. Toxicity of these therapies can result in serious adverse events that can become life-threatening. In particular, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are now the most common adverse effects resulting from chimeric antigen receptor (CAR) T-cell therapy. Furthermore, CAR T cells are reported to cause hyperactivation of macrophages, which in extreme cases results in hemophagocytic lymphohistiocytosis (HLH). These toxic effects result from cytokines released as a direct effect of the therapy. Physicians are evaluating inflammatory markers to monitor longitudinally cytokine stimulation and immune activation after therapy, which can help predict and gauge the severity of the cytokine storm. Prompt recognition of toxic effects and rapid intervention are essential in the management of patients receiving CAR T-cell therapy. Despite intervention, some patients still experience severe and prolonged ICANS. Herein we present a patient with lymphoma who developed prolonged ICANS and reviewed the literature on neurotoxicity and macrophage activation resulting from CD19-directed CAR T-cell therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI